Dashboard
Manage Tickers

GDTC CytoMed Therapeutics Ltd

Nasdaq w2.cytomed.sg


$ 2.28 $ 0.00 (0 %)    

Thursday, 16-Oct-2025 17:04:02 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 597.49 $ -2.23 (-0.37 %)
DIA $ 458.55 $ -3.15 (-0.68 %)
SPY $ 658.17 $ -4.53 (-0.68 %)
TLT $ 91.43 $ 0.68 (0.75 %)
GLD $ 401.51 $ 9.06 (2.34 %)
$ 2.25
$ 2.17
$ 2.11 x 100
$ 2.41 x 1,100
$ 2.15 - $ 2.34
$ 1.65 - $ 4.05
31,061
na
25.97M
$ 0.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cytomed-therapeutics-submits-cash-bid-to-acquire-tc-biopharm-terms-not-disclosed
CytoMed Therapeutics Submits Cash Bid To A...
10/14/2025 12:04:40

SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"...

cytomed-expands-clinical-scale-nk-cells-from-decade-old-cord-blood-forms-new-cord-blood-derived-biotech-under-longevitybank-to-drive-growth-and-revenue
CytoMed Expands Clinical-Scale NK Cells Fr...
08/28/2025 13:07:25

CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharma...

reported-earlier-cytomed-therapeutics-limited-announces-at-the-market-offering-program-for-up-to-43m-in-ordinary-shares-through-rf-lafferty--co-inc
Reported Earlier, CytoMed Therapeutics Lim...
08/19/2025 06:32:56

The Company intends to use the proceeds from the ATM program for general corporate purposes, which may include business diversi...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/23/2025 17:06:04

cytomed-therapeutics-completes-dose-level-1-for-its-first-in-human-phase-i-dose-escalation-clinical-trial-nct05302037-for-four-late-stage-cancer-patients-and-is-scheduled-to-start-dose-level-2-of-the-angelica-trial-in-q3-2025
CytoMed Therapeutics Completes Dose Level ...
07/21/2025 14:04:10

cytomed-therapeutics-files-for-mixed-shelf-of-up-to-50m
CytoMed Therapeutics Files For Mixed Shelf...
06/13/2025 20:25:29

-SEC Filing

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
02/10/2025 21:05:43

cytomed-therapeutics-chairman-sends-letter-to-shareholders-intends-to-implement-radical-revenue-generating-methods
CytoMed Therapeutics Chairman Sends Letter...
02/06/2025 12:48:50

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
01/13/2025 12:05:38

why-inari-medical-shares-are-trading-higher-by-21-here-are-20-stocks-moving-premarket
Why Inari Medical Shares Are Trading Highe...
01/07/2025 12:15:03

singapore-based-cytomed-therapeutics-stock-dips-after-sunact-joins-clinical-trial-as-joint-sponsor
Singapore-Based CytoMed Therapeutics Stock...
01/06/2025 16:10:38

CytoMed Therapeutics teams with SunAct for a Phase 1/2 trial on gamma delta T cells in cancer therapy, advancing affordable imm...

cytomed-therapeutics-shares-are-trading-higher-after-the-company-announced-it-entered-into-a-business-and-research-collaboration-agreement-with-mumbai-based-sunact-cancer-institute
CytoMed Therapeutics shares are trading hi...
01/06/2025 13:48:29

cytomed-therapeutics-has-entered-into-a-business--research-collaboration-agreement-with-mumbai-based-sunact-cancer-institute-private
CytoMed Therapeutics Has Entered Into A Bu...
01/06/2025 12:05:05

The collaboration forms a collaborative effort between CytoMed and SunAct to explore and investigate the safety, tolerability, ...

cytomed-therapeutics-has-dosed-the-first-patient-in-its-first-in-human-phase-i-dose-escalation-angelica-trial-of-allogeneic-nkg2dl-targeting-chimeric-antigen-receptor-grafted-gamma-delta-t-cells-in-patients-with-advanced-solid-tumors-or-hematological-malignancies
CytoMed Therapeutics Has Dosed The First P...
11/20/2024 12:12:42

benchmark-reiterates-speculative-buy-on-cytomed-therapeutics-maintains-5-price-target
Benchmark Reiterates Speculative Buy on Cy...
10/10/2024 13:19:11

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price ...

cytomed-therapeutics-has-acquired-the-license-and-certain-assets-of-cellsafe-international-a-malaysian-cord-blood-bank-deal-terms-were-not-disclosed
CytoMed Therapeutics Has Acquired The Lice...
10/03/2024 11:34:32

The acquisition includes (i) a cord blood banking licence issued by Malaysia's Ministry of Health, (ii) cryopreservation eq...

cytomed-therapeutics-through-its-wholly-owned-subsidiary-ipsc-depository-acquired-the-licence-and-certain-assets-of-cellsafe-international-for-a-cash-consideration-of-about-rm-23m-or-490000-to-be-funded-from-internal-cash-resources
Cytomed Therapeutics, Through Its Wholly O...
07/17/2024 11:11:54

benchmark-reiterates-speculative-buy-on-cytomed-therapeutics-maintains-5-price-target
Benchmark Reiterates Speculative Buy on Cy...
06/11/2024 11:33:29

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price ...

cytomed-therapeutics-diversifies-into-regenerative-medicine-after-research-collaboration-with-singapores-sengkang-general-hospital
CytoMed Therapeutics Diversifies Into Rege...
03/20/2024 12:46:24

cytomed-therapeutics-has-obtained-board-approval-to-launch-pilot-program-to-isolate-and-cryo-store-peripheral-blood-mononuclear-cells-for-and-as-a-reward-to-loyal-shareholders-of-cytomed-on-complimentary-basis-the-program-will-commence-on-june-1-2024
CytoMed Therapeutics Has Obtained Board Ap...
03/18/2024 10:16:10

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION